• Anteris will move to the US and list on Nasdaq, aiming for an IPO
  • LTR Pharma teams up with Aptar to advance Spontan
  • CSL reports a 25pc rise in NPAT, and signals revenue growth in FY25

 

Anteris to relocate to US and list on Nasdaq

Anteris Technologies (ASX:AVR) is planning to relocate its headquarters to the United States, becoming Anteris Technologies Global Corp. (Holdco).

Anteris develops advanced medical technologies, with a focus on its DurAVR transcatheter heart valve for treating severe aortic stenosis.

The move will involve a re-domiciliation process where Holdco will replace Anteris as the parent company.

As part of this transition, Holdco will seek a primary listing on Nasdaq and a secondary listing of its CHESS Depositary Interests (CDIs) on the ASX.

Additionally, Holdco intends to conduct an IPO primarily targeting US investors, with the aim of completing both the re-domiciliation and IPO by the end of 2024.

The re-domiciliation will require Anteris’ shareholders and option holders to exchange their current holdings for equivalent securities in Holdco.

The IPO proceeds are expected to fund the continued development of the DurAVR transcatheter heart valve, and support its FDA pivotal trial.

The board of Anteris believes the re-domiciliation will offer significant benefits, including access to a broader pool of US investors, increased analyst coverage, and potential for acquisitions or partnerships.

The re-domiciliation aligns with the company’s substantial operations already based in the US.

Holdco plans to raise between US$75 million and US$100 million through the IPO. The actual amount raised will depend on market conditions and investor interest.

 

LTR Pharma and Aptar partner to advance Spontan

LTR Pharma (ASX:LTP) has signed a Co-Development Agreement with Aptar Pharma to advance Spontan in global markets.

Spontan is a fast-acting, on-demand nasal spray treatment for erectile dysfunction (ED).

This agreement combines LTP’s development expertise with Aptar’s specialised knowledge in nasal spray technology.

Aptar, known for its leadership in drug delivery systems, will provide crucial support, including regulatory and analytical services, to help navigate the FDA’s expedited 505(b)(2) approval process for Spontan.

The primary aim of the partnership is to commercialise Spontan in the US and other significant international markets.

“As part of this, we will gain access to Aptar’s expertise in the VP7 nasal spray system and related specialised services to support our FDA application process,” said LTR’s Chairman, Lee Rodne.

“This vastly de-risks the FDA application process and elevates the profile of LTR Pharma as a long-term partner of a global market innovator, which we anticipate may create opportunities for other products with alternative indications in future.”

 

CSL reports strong growth

Australia’s biggest healthcare company, CSL(ASX:CSL), has reported a strong performance for the year ending June 30.

Bottom line NPAT came in at $2.64 billion, up 25% on a constant currency basis.

Revenue reached $14.8 billion, up 11% at constant currency.

Its subsidiary, CSL Behring, drove growth with a 14% rise in total revenue and a 20% increase in immunoglobulin sales.

CSL Seqirus saw a 4% revenue increase, largely due to the success of the FLUAD vaccine.

CSL Vifor continued to grow despite new competition.

The company’s balance sheet remains strong with net assets of $19.4 billion and net debt to EBITDA at 2.2 times.

For FY25, CSL expects revenue growth of 5-7% and NPATA to be between $3.2 billion and $3.3 billion.

 

 

Read MoreBiotech

Featured Companies

You might be interested in